| Summary: | Omalizumab was previously reviewed by the Canadian Expert Drug Advisory Committee (CEDAC) in March 2006 for the treatment of moderate to severe persistent asthma in adults and adolescents greater than or equal to 12 years whose symptoms are inadequately controlled with inhaled corticosteroids (ICS), and received a recommendation of "do not list". CADTH has previously produced a Rapid Response Summary of Abstracts in November 2011 assessing the clinical and cost-effectiveness of omalizumab for the treatment of allergic asthma in adults and children who are not responsive to other therapies and found that omalizumab decreased the risk of asthma exacerbations and was found by most studies to be cost-effective due to the health benefits achieved. The purpose of this review is to provide an update to the 2011 CADTH Rapid Response report and provide a full summary with critical appraisal by assessing the clinical and cost-effectiveness of omalizumab for the treatment of allergic asthma in adults and children who are not responsive to other therapies, and identifying evidence-based guidelines regarding the use of omalizumab in these patient populations
|
|---|